2006
DOI: 10.1056/nejmoa044397
|View full text |Cite
|
Sign up to set email alerts
|

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

Abstract: Natalizumab reduced the risk of the sustained progression of disability and the rate of clinical relapse in patients with relapsing multiple sclerosis. Adhesion-molecule inhibitors hold promise as an effective treatment for relapsing multiple sclerosis. (ClinicalTrials.gov number, NCT00027300.).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

82
2,380
13
101

Year Published

2006
2006
2017
2017

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 3,006 publications
(2,576 citation statements)
references
References 30 publications
82
2,380
13
101
Order By: Relevance
“…Case information for seven published cases was reviewed (Table 2) 2, 18, 19, 20, 21, 22, 23. Among the seven cases, six patients were female.…”
Section: Resultsmentioning
confidence: 99%
See 4 more Smart Citations
“…Case information for seven published cases was reviewed (Table 2) 2, 18, 19, 20, 21, 22, 23. Among the seven cases, six patients were female.…”
Section: Resultsmentioning
confidence: 99%
“…The median age of the patients was 41 years at the time of diagnosis of melanoma (range: 38–48 years). Three patients were enrolled in clinical trials evaluating natalizumab when melanoma was diagnosed, including two patients who were enrolled on a prospective phase III randomized trial at the time of diagnosis of melanoma 18, 21, 24. One 38‐year‐old male was enrolled on the randomized phase III study comparing natalizumab versus placebo.…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations